 CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which can treat 155,000 newly diagnosed advanced primary head and neck cancer patients per year globally. Five-year survival: control arm 48.6, Multikine arm 62.7 N380, p0.0236, HR0.68; in other words, 21,000 more patients would be alive after five years versus the current standard of care. 